How many drugs treat Neuroendocrine tumor?

Drug Landscape tracks 1 marketed treatments for Neuroendocrine tumor (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/neuroendocrine-tumor.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Neuroendocrine tumor — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuroendocrine tumor (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neuroendocrine tumor, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Lutathera	lutetium (177Lu) oxodotreotide	Aaa Usa Inc		Somatostatin receptor type 2		2018-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Aaa Usa Inc · 1 drug in Neuroendocrine tumor

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neuroendocrine tumor:

Cite this brief

Drug Landscape (2026). Neuroendocrine tumor — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neuroendocrine-tumor. Accessed 2026-06-10.

Neuroendocrine tumor full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing